Stock Analysis

Zimmer Biomet Holdings (NYSE:ZBH) Could Be At Risk Of Shrinking As A Company

  •  Updated
NYSE:ZBH
Source: Shutterstock

What financial metrics can indicate to us that a company is maturing or even in decline? A business that's potentially in decline often shows two trends, a return on capital employed (ROCE) that's declining, and a base of capital employed that's also declining. This indicates the company is producing less profit from its investments and its total assets are decreasing. So after we looked into Zimmer Biomet Holdings (NYSE:ZBH), the trends above didn't look too great.

What is Return On Capital Employed (ROCE)?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Zimmer Biomet Holdings is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.043 = US$947m ÷ (US$24b - US$2.1b) (Based on the trailing twelve months to March 2021).

Therefore, Zimmer Biomet Holdings has an ROCE of 4.3%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 8.4%.

View our latest analysis for Zimmer Biomet Holdings

roce
NYSE:ZBH Return on Capital Employed May 25th 2021

Above you can see how the current ROCE for Zimmer Biomet Holdings compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

The Trend Of ROCE

There is reason to be cautious about Zimmer Biomet Holdings, given the returns are trending downwards. About five years ago, returns on capital were 7.1%, however they're now substantially lower than that as we saw above. Meanwhile, capital employed in the business has stayed roughly the flat over the period. Since returns are falling and the business has the same amount of assets employed, this can suggest it's a mature business that hasn't had much growth in the last five years. So because these trends aren't typically conducive to creating a multi-bagger, we wouldn't hold our breath on Zimmer Biomet Holdings becoming one if things continue as they have.

In Conclusion...

In summary, it's unfortunate that Zimmer Biomet Holdings is generating lower returns from the same amount of capital. But investors must be expecting an improvement of sorts because over the last five yearsthe stock has delivered a respectable 42% return. Regardless, we don't feel too comfortable with the fundamentals so we'd be steering clear of this stock for now.

Since virtually every company faces some risks, it's worth knowing what they are, and we've spotted 2 warning signs for Zimmer Biomet Holdings (of which 1 makes us a bit uncomfortable!) that you should know about.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

If you’re looking to trade Zimmer Biomet Holdings, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


What are the risks and opportunities for Zimmer Biomet Holdings?

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

View Full Analysis

Rewards

  • Earnings are forecast to grow 21.48% per year

Risks

  • Profit margins (4.1%) are lower than last year (11.7%)

  • Large one-off items impacting financial results

  • Has a high level of debt

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Zimmer Biomet Holdings

ValuationFinancial HealthInsider TradingManagement Team